For the quarter ending 2025-09-30, MURA had -$18,481K decrease in cash & cash equivalents over the period. -$18,481K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Depreciation | - | 2,000 |
| Net loss | -3,706 | -81,119 |
| Impairment on lab equipment held-for-sale | - | 3,000 |
| Depreciation | 797 | 1,991 |
| Impairment on lab equipment held-for-sale | 271 | 2,975 |
| Write-off of prepaid expenses related to program terminations | 0 | 2,549 |
| Share-based compensation expense | 109 | -608 |
| Amortization of discount on marketable securities | 0 | 97 |
| Receivable from former parent | 0 | -51 |
| Prepaid expenses | -309 | -3,606 |
| Other current assets | -608 | -283 |
| Right-of-use assets | -1,227 | -2,422 |
| Other assets | 0 | -10 |
| Accounts payable and accrued expenses | -16,472 | 2,672 |
| Operating lease liabilities | -1,626 | -2,849 |
| Other liabilities | 2 | -47 |
| Cash flows used in operating activities | -18,481 | -68,161 |
| Purchases of marketable securities | 0 | 0 |
| Sales and maturities of marketable securities | 0 | 29,000 |
| Proceeds from sale of property and equipment | 0 | 780 |
| Additions of property and equipment | 0 | 15 |
| Cash flows provided by (used in) investing activities | 0 | 29,765 |
| Proceeds from issuance of ordinary shares under employee share plans | 0 | 28 |
| Cash flows provided by financing activities | 0 | 28 |
| Net decrease in cash, cash equivalents and restricted cash | -18,481 | -38,368 |
| Cash and cash equivalents at beginning of period | 117,431 | - |
| Cash and cash equivalents at end of period | 60,582 | - |
Mural Oncology plc (MURA)
Mural Oncology plc (MURA)